TUBB3 mRNA表达对紫杉醇化疗晚期非小细胞肺癌患者疗效的影响  被引量:2

Effect Analysis of TUBB3m RNA Expression on Paclitaxel Chemotherapy for Advanced Non-small cell Lung Cancer Patients

在线阅读下载全文

作  者:崔海靖[1] 窦珊珊[1] 张秀霞[1] 沈丽英[2] 

机构地区:[1]石家庄市第一医院肿瘤科,河北石家庄050011 [2]第四军医大学西京医院呼吸科,陕西西安710032

出  处:《现代生物医学进展》2013年第25期4881-4884,共4页Progress in Modern Biomedicine

基  金:河北省石家庄市科技局立项(10146733)

摘  要:目的:探讨TUBB3 mRNA表达对紫杉醇化疗晚期非小细胞肺癌患者疗效影响。方法:对我院收治的100例晚期非小细胞肺癌患者根据其TUBB3 mRNA表达情况将其分为阳性组55例和阴性组45例,对两组患者均采用紫杉醇联合顺铂进行治疗,分析两组患者的临床资料以及预后。结果:两组患者的临床资料无明显差异性,而阴性组患者在客观缓解率、部分缓解率、疾病进展率、总生存时间以及至肿瘤进展时间均优于对照组(P<0.05)。阳性组在性别、年龄、淋巴结转移、TNM分期的比较中无差异,而在病理分型中(鳞癌/腺癌)的比较中存在显著性差异。结论:TUBB3 mRNA阴性表达的患者其采用紫杉醇联合顺铂进行治疗可明显延长患者生存时间。Objective: To investigate TUBB3 mRNA expression paclitaxel chemotherapy for advanced non-small cell lung cancer patients with curative effect. Method: TUBB3 mRNA expression of our hospital 100 patients with small cell lung cancer patients with late fee were divided into positive group 55 cases and 45 cases of negative group, two groups of patients, were treated with paclitaxel plus cis- platin clinical data and prognosis of the patients were analyzed. Results: There were no significant difference in two groups of pa- tients with clinical data, negative patients, the objective response rate, partial response rate, the rate of disease progression, overall sur- vival time and time to tumor progression (P〈0.05). Gender, age, lymph node metastasis, TNM staging comparison was no difference in positive group, end there was a significant difference in tho pahological type (squamous cell carcinoma / adenocarcinoma) comparison. Conclusion: TUBB3 mRNA in patients with negative expression with paclitaxel plus cisplatin treatrTmx can significantly prolong the survival tirne.

关 键 词:3型β微管蛋白 紫杉醇 非小细胞肺癌 

分 类 号:R734.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象